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Phyllodes tumors (PTs) are biphasic tumors accounting for 0.3–1.5% of all breast tumors.
Epithelial membrane proteins (EMPs) have been reported in various malignant tumors but
their expression in PTs is unclear. In this study, we aimed to evaluate the expression of
EMP1, EMP2, and EMP3 in breast phyllodes tumors (PTs), and to investigate their clinical
implications.
Methods
In total, 185 PTs were used for constructing a tissue microarray. Immunohistochemical
staining for EMP1, EMP2, and EMP3 was performed, and the results were analyzed along
with the clinicopathologic parameters.
Results
In total, 185 PTs were included in this study, and comprised 138 benign, 32 borderline, and
15 malignant PTs. In malignant PTs, the epithelial component showed decreased expres-
sion of EMP1 (P = 0.027), EMP2 (P = 0.004), and EMP3 (P = 0.032), compared to the
benign and borderline PTs. Conversely, stromal component of borderline and malignant
PTs showed higher expression of EMP1 (P = 0.027), EMP2 (P = 0.004), and EMP3 (P =
0.032) compared to benign PTs. Expression of EMP1 and EMP3 correlated positively with
stromal cellularity and cellular atypia (P < 0.001). In the univariate analysis, stromal EMP3
was associated with shorter disease-free survival (P < 0.001), and shorter overall survival
(P = 0.034).
Conclusion
The expression of EMP1, EMP2, and EMP3 is decreased in the epithelial component and is
increased in the stromal component of PT with higher histologic grade. Thus, stromal EMP3
expression may serve as an independent prognostic factor in PT.
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Introduction
Phyllodes tumors (PT) are biphasic tumors accounting for 0.3–1.5% of all breast tumors. The
World Health Organization (WHO) classifies PTs as benign, borderline, and malignant based
on the evaluation of the stromal component [1]. PTs can recur and metastasize heteroge-
neously [1]. Although their stromal component is considered the main neoplastic element in
PT [2], epithelial-stromal interaction is also thought to be involved in PT pathogenesis. The
epithelial-stromal interaction of PTs is suggested to involve the Wnt pathway [3], platelet-
derived growth factor (PDGF)/PDGF receptor(R)-β pathway [4], insulin-like growth factor
(IGF)-I/II [5], and C-X-C receptor type 4 (CXCR4) [6]. The MED12 mutation is also known
as a driver of tumorigenesis in fibroepithelial tumors [7, 8]. Recently, two mechanisms are sug-
gested to underlie the progression of the histologic grade of PT: fibroepithelial tumor and
benign PT show frequent somatic MED12 mutation and additional genetic alterations are
found with increasing histologic grade, whereas borderline/malignant PTs without MED12
mutation frequently harbor TP53 and PIK3CA mutations [9, 10].
Epithelial membrane proteins (EMPs; EMP1, EMP2, and EMP3) are members of the
peripheral myelin protein (PMP22) gene family [11]. EMP1 is a target of c-MYC [12], and is
highly expressed in undifferentiated cells [13]; it has been reported as a negative regulator in
some cancers including nasopharyngeal cancer [14], and breast cancer [15]. EMP2 has been
considered an oncogene, particularly in hormone-related cancers such as endometrial and
breast cancer [16, 17]. EMP3 appears to be a tumor suppressor gene in solid tumors [18]. So
far, EMPs have been evaluated in various malignant tumors, particularly, brain tumors and
carcinomas. However, EMP expression in breast PTs has not been elucidated. As PT is a
biphasic neoplasm, EMP expression in both epithelial and stromal components, as well as in
different histologic grades, is expected to differ. In the present study, we aimed to evaluate the
expression and clinical implications of EMP1, EMP2, and EMP3 in breast PTs.
Materials and methods
Patient selection
Tissue samples were collected from patients with a pathologically confirmed diagnosis of PT
who underwent resection at the Severance hospital between 2000 and 2010. The study was
approved by the Institutional review board of Yonsei university, Severance hospital, with wav-
ier of informed consent. All clinical data were anonymized. All tissues were fixed in 10% buff-
ered formalin and embedded in paraffin. All archival hematoxylin and eosin (H&E)-stained
slides for each case were reviewed by two pathologists (JS Koo and YJ Cha), and all PTs were
assigned a histologic grade based on the WHO classification [1]. Clinical factors including
patient age at diagnosis, tumor recurrence, distant metastasis, and patient survival were
examined.
Tissue microarray
On H&E-stained slides of tumors, a representative area was selected, and the corresponding
spot was marked on the surface of the paraffin block. Using a biopsy needle, the selected area
was punched out and the resulting 5-mm tissue core was placed in a 5 × 6 recipient block. Two
tissue cores were extracted from each case to minimize extraction bias. Each separate tissue
core was assigned a unique tissue microarray location number that was linked to a database
including other clinicopathologic data.
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data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Immunohistochemistry and interpretation
The antibodies used for immunohistochemistry in this study are shown in Table 1. All immu-
nostaining procedures were performed using formalin-fixed, paraffin-embedded tissue sec-
tions. Briefly, 5-μm-thick sections were prepared using a microtome, transferred to adhesive
Table 1. Source, clone, and dilution of the antibodies used.
Antibody Company Clone Dilution
EMP1 Abcam, Cambridge, UK N-terminal 1:100
EMP2 Abcam, Cambridge, UK C-terminal 1:100
EMP3 Santa Cruz Biotechnology, CA, USA SW-5 1:100
EMP, epithelial membrane protein.
https://doi.org/10.1371/journal.pone.0238466.t001
Table 2. Clinicopathologic characteristics of patients with phyllodes tumor.
Parameters Total N = 185 (%) PT, benign N = 138 (%) PT, borderline N = 32 (%) PT, malignant N = 15 (%) P-value
Age, years (mean ± SD) 40.4 ± 12.2 39.1 ± 12.1 43.2 ± 11.0 47.6 ± 13.4 0.013
Tumor size, cm (mean ± SD) 4.0 ± 2.6 3.7 ± 2.2 4.2 ± 2.5 6.2 ± 4.3 0.001
Stromal cellularity <0.001
Mild 107 (57.8) 105 (76.1) 2 (6.3) 0 (0.0)
Moderate 66 (35.7) 33 (23.9) 26 (81.3) 7 (46.7)
Marked 12 (6.5) 0 (0.0) 4 (12.5) 8 (53.3)
Stromal atypia <0.001
Mild 143 (77.3) 136 (98.6) 7 (21.9) 0 (0.0)
Moderate 32 (17.3) 2 (1.4) 22 (68.8) 8 (53.3)
Marked 10 (5.4) 0 (0.0) 3 (9.4) 7 (46.7)
Stromal mitosis (per 10 HPFs) <0.001
0–4 142 (76.8) 138 (100.0) 4 (12.5) 0 (0.0)
5–9 33 (17.8) 0 (0.0) 28 (87.5) 5 (33.3)
� 10 10 (5.4) 0 (0.0) 0 (0.0) 10 (66.7)
Stromal overgrowth <0.001
Absent 169 (91.4) 138 (100.0) 29 (90.6) 2 (13.3)
Present 16 (8.6) 0 (0.0) 3 (9.4) 13 (86.7)
Tumor margin <0.001
Circumscribed 166 (89.7) 135 (97.8) 25 (78.1) 6 (40.0)
Infiltrative 19 (10.3) 3 (2.2) 7 (21.9) 9 (60.0)
Surgical procedure <0.001
Local excision 136 (73.5) 119 (86.2) 16 (50.0) 1 (6.7)
Wide excision 38 (20.5) 14 (10.1) 15 (46.9) 9 (60.0)
Mastectomy 11 (5.9) 5 (3.6) 1 (3.1) 5 (33.3)
Margin status 0.928
Negative 160 (86.5) 120 (87.0) 27 (84.4) 13 (86.7)
Positive 25 (13.5) 18 (13.0) 5 (15.6) 2 (13.3)
Tumor local recurrence 17 (9.2) 5 (3.6) 5 (15.6) 7 (46.7) <0.001
Distance metastasis 7 (3.8) 0 (0.0) 0 (0.0) 7 (46.7) <0.001
Follow-up, months (median, range) 63 (8–183) 73 (14–183) 59 (12–144) 15 (8–62) <0.001
PT, phyllodes tumor; SD, standard deviation; HPFs, high power fields.
https://doi.org/10.1371/journal.pone.0238466.t002
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slides, and dried at 62˚C for 30 minutes. After incubation with primary antibodies, immuno-
detection was performed with biotinylated anti-mouse immunoglobulin, followed by peroxi-
dase-labeled streptavidin using a labeled streptavidin biotin kit with 3,30-diaminobenzidine as
the chromogenic substrate. Appropriate positive and negative controls were included. Slides
were counterstained with Harris hematoxylin. The staining of all immunohistochemical mark-
ers was assessed by light microscopy and samples were scored by multiplying the proportion
of stained cells (0%, negative; 1, <30% positivity, 2;�30% positivity) with the staining inten-
sity (0, negative; 1, weak; 2, moderate; 3, strong). Representative pictures of staining is shown
in S1 and S2 Figs. Multiplied values of 0 and 1 were considered as negative whereas values of 2
or more were considered as positive [19].
Statistical analysis
Data were analyzed using SPSS for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA). For
determination of statistical significance, Student’s t test and Fisher’s exact test were used for
continuous and categorical variables, respectively. Statistical significance was considered at
P< 0.05. Kaplan-Meier survival curves and log-rank statistics were employed to evaluate the
time to tumor recurrence. Multivariate regression analysis was performed using the Cox pro-
portional hazards model.
Results
Basal characteristics of PTs
Table 2 shows the basal clinical characteristics of patients. In total, 185 cases were included in
this study and were composed of 138 benign, 32 borderline, and 15 malignant PTs. Increasing
Table 3. Expression of EMP1, EMP2, and EMP3 in phyllodes tumors.
Parameters Total N = 185 (%) PT, benign N = 138 (%) PT, borderline N = 32 (%) PT, malignant N = 15 (%) P-value
EMP1 (E)� 0.027
Negative 9 (5.4) 5 (3.6) 3 (11.1) 1 (33.3)
Positive 159 (94.6) 133 (96.4) 24 (88.9) 2 (66.7)
EMP1 (S) <0.001
Negative 81 (43.8) 75 (54.3) 3 (9.4) 3 (20.0)
Positive 104 (56.2) 63 (45.7) 29 (90.6) 12 (80.0)
EMP2 (E)� 0.004
Negative 39 (23.2) 32 (23.2) 4 (14.8) 3 (100.0)
Positive 129 (76.8) 106 (76.8) 23 (85.2) 0 (0.0)
EMP2 (S) <0.001
Negative 176 (95.1) 137 (99.3) 26 (81.3) 13 (86.7)
Positive 9 (4.9) 1 (0.7) 6 (18.8) 2 (13.3)
EMP3 (E)� 0.032
Negative 24 (14.3) 18 (13.0) 4 (14.8) 2 (66.7)
Positive 144 (85.7) 120 (87.0) 23 (85.2) 1 (33.3)
EMP3 (S) <0.001
Negative 137 (74.1) 118 (85.5) 13 (40.6) 6 (40.0)
Positive 48 (25.9) 20 (14.5) 19 (59.4) 9 (60.0)
�Seventeen tumors without an epithelial component were excluded.
PT, phyllodes tumor; EMP, epithelial membrane protein; E, epithelial staining; S, stromal staining.
https://doi.org/10.1371/journal.pone.0238466.t003
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age and tumor size were associated with the histologic grade of PT (P = 0.013, and P = 0.001,
respectively). Tumor recurrence and distant metastasis were more frequent with higher histo-
logic grade (P< 0.001). Seven PTs showed distant metastasis, and the metastatic site for all
cases was the lung (Table 2).
EMP1, EMP2, and EMP3 expression according to the PT grades
The expression of EMP1, EMP2, and EMP3 in both the epithelial and stromal components dif-
fered according to the histologic grade (Table 3). EMP1 (P = 0.027), EMP2 (P = 0.004), and
EMP3 (P = 0.032) expression in the epithelial component showed an inverse correlation with
the histologic grade. In contrast, EMP1 (P = 0.027), EMP2 (P = 0.004), and EMP3 (P = 0.032)
expression in the stromal component was higher in borderline and malignant PTs compared
to that in benign PTs (Fig 1).
Fig 1. Representative histologic images of hematoxylin and eosin staining and immunohistochemical staining for
EMP1, EMP2, and EMP3 in phyllodes tumors with different histologic grades. The expression of EMPs is the strongest in
the epithelial component of benign phyllodes tumors (PT). Notably, strong stromal expression of EMP1, EMP2, and EMP3 is
observed in malignant PT.
https://doi.org/10.1371/journal.pone.0238466.g001
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Correlation between EMP1, EMP2, and EMP3 expression in PTs and
pathologic parameters
Stromal positivity of EMP1 and EMP3 was associated with stromal cellularity and stromal cell
atypia. EMP1 expression was positively correlated with increasing stromal cellularity and cellu-
lar atypia (P< 0.001, Fig 2).
Impact of EMP1, EMP2, and EMP3 expression on patient prognosis
In univariate analysis, stromal EMP3 expression was associated with shorter disease-free sur-
vival (P< 0.001) and shorter overall survival (OS) (P = 0.034) (Table 4, Fig 3). However, no
significant difference for stromal EMP3 expression was found by multivariate Cox analysis
(Table 5).
Discussion
We evaluated the expression of EMP1, EMP2, and EMP3 in PTs of the breast, and found that
EMP expression was reduced in the epithelial component and was increased in the stromal
component, along with increasing histologic grade. Although the epithelial component
showed a different expression pattern–an inverse correlation with stromal expression–we
focused on the stromal component in the present study because the stromal component is the
neoplastic element and determines the diagnosis and tumor grade. Although PTs account for a
far lesser proportion of breast fibroepithelial lesions compared to fibroadenomas, both lesions
Fig 2. Association of histology and the expression of EMP1 and EMP3. Increased stromal cellularity and stromal
atypia are correlated with the expression rate of EMP1 (A and B) and EMP3 (C and D) S, stromal.
https://doi.org/10.1371/journal.pone.0238466.g002
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share histomorphological features [20, 21], as well as genetic alterations such as recurrent
MED12 mutations [7, 22–24].
In the present study, stromal EMPs showed significantly increased expression in border-
line/malignant PTs, but only stromal EMP3 expression was identified as an independent risk
factor for short OS. Considering that EMP1, EMP2, and EMP3 have been reported to play
important roles in various malignant tumors [25], increased expression of EMP1 and EMP3,
along with stromal cellularity and stromal atypia, imply that increased EMP expression in PT
could suggest a higher malignant potential for PT. EMP1 also showed a tendency for increased
Table 4. Univariate analysis of the impact of EMP1, EMP2, and EMP3 expression in phyllodes tumors.
Parameters No. of patients (%) Total/recurrence/metastasis Disease-free survival Overall survival
Median months (range) P-value Median months (range) P -value
EMP1 (E)� N/A N/A
Negative 9 (100.0) / 0 (0.0) / 0 (0.0) N/A N/A
Positive 159 (100.0) / 10 (6.3) /1 (0.6) N/A N/A
EMP1 (S) 0.364 N/A
Negative 81 (100.0) / 6 (7.4) / 0 (0.0) 166 (156–176) N/A
Positive 104 (100.0) / 11 (10.6) / 7(6.7) 162 (151–174) N/A
EMP2 (E)� 0.642 N/A
Negative 39 (100.0) / 2 (5.1) / 0 (0.0) 169 (158–179) N/A
Positive 129 (100.0) /8 (6.2) / 1 (0.8) 171 (163–179) N/A
EMP2 (S) N/A N/A
Negative 176 (100.0) / 17 (9.7) / 7 (4.0) N/A N/A
Positive 9 (100.0) / 0 (0.0) / 0 (0.0) N/A N/A
EMP3 (E)� 0.687 N/A
Negative 24 (100.0) / 2 (8.3) / 0 (0.0) 134 (119–148) N/A
Positive 144 (100.0) / 8 (5.6) /1 (0.7) 172 (165–179) N/A
EMP3 (S) <0.001 0.034
Negative 137 (100.0) / 7 (5.1) / 3 (2.2) 173 (167–180) 179 (174–183)
Positive 48 (100.0) / 10 (20.8) / 4 (8.3) 138 (116–159) 163 (150–176)
�Seventeen tumors without an epithelial component were excluded.
PT, phyllodes tumor; EMP, epithelial membrane protein; E, epithelial staining; S, stromal staining.
https://doi.org/10.1371/journal.pone.0238466.t004
Fig 3. Disease-free survival and overall survival based on EMP3 expression. Cases with stromal EMP3 expression
show inferior prognosis with regard to disease-free survival (A) and overall survival (B). S, stromal.
https://doi.org/10.1371/journal.pone.0238466.g003
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expression in the stroma along with an increase in the histologic grade, but did not impact
prognosis. Conversely, stromal EMP2 expression was only found in a few cases (N = 9), no fur-
ther statistical meaning could be found.
A previous study has shown that EMP3 is hypermethylated in approximately 20–40% of
neuroblastoma and glioma cases, and plays a role in tumor suppression, which is also related
with patients’ prognosis [26]. As most previous studies regarding EMPs had used epithelial
carcinoma and a few had used glioma, this study was important as it determined the role of
EMP3 in non-epithelial tumors, similar to the present study. Another recent study on high-
grade glioma showed high expression of EMP3, particularly in CD44-high glioblastoma [27],
which refuted the result of a prior study on glioma [26]. However, CD44-high glioblastoma is
different from the general cases of glioma; it is classified as the mesenchymal subclass within
glioblastoma. EMP3 expression was found to be correlated with the activation of TGF-β/
Smad2/3 signaling by interaction with TGFBR2, which resulted in TGF-β stimulated gene
expression and tumor cell proliferation [27]. TGF-β signaling generally enhances epithelial
mesenchymal transition (EMT) [28, 29], but it also activates the proliferation of tumor cells of
non-epithelial origin [30, 31]. In gastric cancer, EMP3 has been suggested as a downstream
effector of TWIST1/2 and a regulator of EMT [32].
Moreover, a previous study showed that malignant PT was more likely to have wild-type
MED12 along with mutations in PIK3CA, which is considered an oncogene [9]. EMP3 and
EMP1 have been reported to be involved in the PI3K/Akt pathway in HCC [33], and in the
tumorigenesis of non-small cell lung cancer [34]. Because research regarding the treatment of
Table 5. Multivariate Cox regression analysis of disease-free and overall survival in patients with phyllodes tumors.
Included factor Disease-free survival Overall survival
HR (95% CI) P-value HR (95% CI) P-value
Histologic grade
Benign Reference Reference
Borderline/malignant 2.435 (0.536–11.060) 0.249 206.6 (3.929–10866) 0.008
Stromal cellularity
Mild Reference Reference
Moderate/marked 1.198 (0.159–9.032) 0.861 0.002 (0.000–8.503) 0.910
Stromal atypia
Mild Reference Reference
Moderate/marked 0.800 (0.111–5.774) 0.825 0.000 (0.000–6.754) 0.881
Stromal mitosis
0-4/10 HPFs Reference Reference
>4/10 HPFs 9.550 (0.781–116.7) 0.077 16125 (0.000–6.538) 0.857
Stromal overgrowth
Absent Reference Reference
Present 3.535 (0.830–15.060) 0.088 30617 (0.000–1.456) 0.862
Tumor margin
Circumscribed Reference Reference
Infiltrative 0.558 (0.159–1.957) 0.362 0.150 (0.013–1.715) 0.127
EMP3 (S)
Negative Reference Reference
Positive 0.523 (0.153–1.787) 0.301 1.841 (0.035–98.090) 0.763
HR, hazard ratio; CI, confidence interval; HPFs, high power fields; EMP, epithelial membrane protein; S, stromal staining.
https://doi.org/10.1371/journal.pone.0238466.t005
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PT is still limited and unclear, mining of effective therapeutic targets is necessary [35, 36]. As
stromal EMP3 expression showed increased expression along with the histologic grade as well
as was intimately associated with tumor aggressiveness and prognosis in the present study, it
might be considered as a good candidate for treatment. Moreover, EMP1 and EMP2, which
also showed increased expression in borderline/malignant PT, should be also evaluated fur-
ther, even though they showed no significant clinical impact in the present study. In the pres-
ent study, EMP2-expressing PTs were too few in number, and were inappropriate for
statistical analysis. However, EMP2 has been reported to be highly expressed in glioblastoma
and in human samples and a mouse model; further, the anti-EMP antibody showed efficacy in
tumor inhibition [37]. Another limitation of the present study is that there is no data evaluates
the EMPs in mesenchymal tumors, probably EMPs are basically epithelial membrane proteins,
as their names. As anti EMP2 antibody could affect the tumor inhibition of glioblastoma, fur-
ther evaluation and validation of EMPs expression in high grade mesenchymal tumors are
required.
In conclusion, the results of this study indicate that stromal expression of EMP1, EMP2,
and EMP3 is increased along with the histologic grade in PT, and that stromal EMP3 expres-
sion is an independent prognostic factor for the survival of patients with breast PTs.
Supporting information
S1 Fig. Scan power view of all immunohistochemistry slides of EMP1, EMP2, and EMP3.
(TIF)
S2 Fig. Higher magnification of immunohistochemistry of EMP1, EMP2, and EMP3.
(TIF)
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